Cefepime/sulbactam combination as a treatment alternative for extended spectrum beta-lacatmase producing Enterobacterales: A multicentric study from India
Background: Piperacillin/tazobactam has limited activity against Enterobacterales, which concurrently express ESBL/ampC/OXA-1 beta-lactamases, which are widely prevalent in India. Thus, there is a severe dearth for carbapenem sparing options that aggravate more dependent carbapenem therapy. In the I...
Saved in:
Main Authors: | Yamuna Devi Bakthavatchalam (Author), Dhanalakshmi Solaimalai (Author), Anand Ashok (Author), Harthi Ragothaman (Author), Soniya Krishnamoorthy (Author), Nivedhana Subburaju (Author), Sanjay bhattacharya (Author), Rudresh Sm (Author), Shripad Murlidhar Taklikar (Author), Barney Isaac (Author), Kamini Walia (Author), Balaji Veeraraghavan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In vitro activity of levonadifloxacin, the active drug of orally administered prodrug alalevonadifloxacin against bloodstream isolates of Burkholderia pseudomallei
by: Yamuna Devi Bakthavatchalam, et al.
Published: (2024) -
In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing <i>Klebsiella pneumoniae</i>: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
by: Snehal Palwe, et al.
Published: (2021) -
The Impact of Cefepime and Ampicillin/Sulbactam on Preventing Post-Cesarean Surgical Site Infections, Randomized Controlled Trail
by: Mona A. Abdelrahman, et al.
Published: (2023) -
Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against <i>Acinetobacter</i> spp.
by: Cristina Lasarte-Monterrubio, et al.
Published: (2021) -
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
by: Dilip Dubey, et al.
Published: (2023)